Tmunity

Closed

Next-generation T-cell therapies for cancer.

Philadelphia, United States · Founded 2015 · $185.0M raised

Employees
1–10
Founded
2015
Business Model
B2B
Total Funding
$185.0M
Last Round
Venture RoundDec 2022
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 4 investors for this company. The full record is or through the API.

About

Tmunity Therapeutics developed next-generation engineered T-cell therapies (CAR-T and TCR-T) for solid tumors and hematologic malignancies in oncology. The company collaborated with biopharma partners and clinical centers before being acquired by Kite, a Gilead Company.

Summary

Tmunity is a Biotech company based in Philadelphia, United States, founded in 2015. It has raised $185.0M in total across 4 rounds, most recently a Venture Round in Dec 2022. Investors include Parker Institute for Cancer Immunotherapy, Andreessen Horowitz and Gilead Sciences.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundSeries CDec 2022

Sign up to see all 4 events

Funding: Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tmunity on Indexed.vc
<a href="https://indexed.vc/companies/tmunity"><img src="https://indexed.vc/api/badge/company/tmunity" alt="Tmunity on Indexed.vc" width="260" height="76" /></a>